urea has been researched along with Myelodysplastic Syndromes in 3 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow." | 1.43 | Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Manero, G | 2 |
| Khoury, HJ | 1 |
| Jabbour, E | 1 |
| Lancet, J | 1 |
| Winski, SL | 2 |
| Cable, L | 1 |
| Rush, S | 1 |
| Maloney, L | 1 |
| Hogeland, G | 2 |
| Ptaszynski, M | 1 |
| Calvo, MC | 1 |
| Bohannan, Z | 1 |
| List, A | 1 |
| Kantarjian, H | 1 |
| Komrokji, R | 1 |
| Gañán-Gómez, I | 1 |
| Bohannan, ZS | 1 |
| Bachegowda, L | 1 |
| Morrone, K | 1 |
| Mantzaris, I | 1 |
| Bartenstein, M | 1 |
| Ramachandra, N | 1 |
| Giricz, O | 1 |
| Sukrithan, V | 1 |
| Nwankwo, G | 1 |
| Shahnaz, S | 1 |
| Bhagat, T | 1 |
| Bhattacharyya, S | 1 |
| Assal, A | 1 |
| Shastri, A | 1 |
| Gordon-Mitchell, S | 1 |
| Pellagatti, A | 1 |
| Boultwood, J | 1 |
| Schinke, C | 1 |
| Yu, Y | 1 |
| Guha, C | 1 |
| Rizzi, J | 1 |
| Garrus, J | 1 |
| Brown, S | 1 |
| Wollenberg, L | 1 |
| Wright, D | 1 |
| Munson, M | 1 |
| Rodriguez, M | 1 |
| Gross, S | 1 |
| Chantry, D | 1 |
| Zou, Y | 1 |
| Platanias, L | 1 |
| Burgess, LE | 1 |
| Pradhan, K | 1 |
| Steidl, U | 1 |
| Verma, A | 1 |
1 trial available for urea and Myelodysplastic Syndromes
| Article | Year |
|---|---|
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle | 2015 |
2 other studies available for urea and Myelodysplastic Syndromes
| Article | Year |
|---|---|
p38 MAPK in MDS.
Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Prot | 2015 |
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; | 2016 |